Ola Sandersson

Partner, Stockholm

Corporate Advisory, Corporate Investigations & Compliance, Equity Capital Markets, Private M&A, Public M&A

Contact

Ola Sandersson is a Stockholm-based Partner and Head of Roschier’s Corporate Advisory practice in Sweden. He is specialized in public and private M&A, equity capital markets, as well as corporate advisory and compliance, and has extensive experience in Nordic and international M&A. Ola regularly acts for domestic and international industrial companies, holding companies and banks. He has also worked with investment banking for Lehman Brothers in London during 2001 and 2002.

Recognitions

Ola is ranked as one of the leading capital markets and M&A experts in Sweden by publications such as Chambers Europe, Chambers Global, IFLR1000 and Lexology Index (formerly Who’s Who Legal), and he is also recommended by The Legal 500.

This is what clients say about Ola:

“Ola Sandersson is extremely friendly and knowledgeable about corporate laws in Sweden, very experienced in public M&A, with superior ability to crystalise complex legal analysis in plain English.”
– The Legal 500 2023, Commercial, Corporate and M&A

“Ola is a skilled and accomplished corporate law specialist who is highly sought after for his expertise in M&A and equity capital markets matters.”
– Who’s Who Legal 2023, Capital Markets

“He is the go-to guy when you need to understand something regarding any Swedish law matter.”
– Chambers Global 2022, Corporate/M&A

Work highlights

Ola Sandersson’s experience includes advising:

  • Mitsubishi Corporation as it enters into an industrial partnership driving sustainable aluminium manufacturing;
  • CVC in the recommended cash offer for Resurs Holding;
  • TA Associates in the fully underwritten SEK 4.3 billion rights issue in Elos Medtech;
  • Cargill in an offtake agreement and the commitment to invest in Nordic Iron Ore;
  • KKR’s life science platform Gamma Biosciences in the USD 215 million sale of Astrea Bioseparations to Biotage;
  • Karo Pharma in connection with EQT’s public offer;
  • Vinted in the SEK 315 million public offer for all shares in Rebelle;
  • CVC Funds and Teniralc in the public offer for all shares in Cary Group;
  • Philip Morris International in its SEK 161 billion public offer for all shares in Swedish Match;
  • Stena Adactum in the SEK 1.2 billion mandatory public offer to the shareholders of Svedbergs;
  • The owners of Sylphar International NV in the sale of the company to Karo Pharma;
  • Veoneer on Swedish regulatory matters in connection with the acquisition of its shares by Qualcomm;
  • TA Associates in connection with the public tender offer for Elos Medtech;
  • LMK Group (Linas Matkasse) and the main shareholder Herkules Capital in the initial public offering of LMK Group’s shares and listing on Nasdaq First North Premier Growth Market;
  • EQT IX and Roar BidCo in their SEK 23.6 billion public offer for Recipharm;
  • Latour Industries in the public offer for Allgon;
  • Searchlight Capital Partners in the acquisition of shares to obtain more than 90% ownership of Opus Group;
  • Stena Adactum and Altor in the public offer for Gunnebo;
  • Nordic Waterproofing in its re-domiciliation through a cross-border reverse merger and listing on Nasdaq Stockholm;
  • Triton on its public offer for HiQ International;
  • KKR Credit in it’s re-negotiated investment in Avida Holding AB;
  • NCAB Group AB (publ) in its directed share issue to Swedish and international institutional investors;
  • Filtronic PLC (listed on AIM operated by the London Stock Exchange) in the sale of its telecoms antenna business to Microdata Telecom Innovation;
  • Walnut Bidco Plc, a newly established company indirectly wholly owned by members of the family af Jochnick, in its public offer to the shareholders of Oriflame Holding AG;
  • A holding company owned by RoundTable Healthcare Partners and Signet Healthcare Partners in the USD 155 million acquisition of Moberg Pharma’s OTC-business, and the contemplated subscription of newly issued series B shares and warrants in Moberg Pharma;
  • Quimper AB (a private company in which CVC Funds have or will indirectly invest) on its cash tender offer for Ahlsell;
  • Magnolia Bostad AB in connection with its list change from Nasdaq First North Premier to Nasdaq Stockholm’s main market;
  • Atlas Copco on the formation and listing of the SEK 105 billion company Epiroc on Nasdaq Stockholm;
  • Ahlsell AB (publ) and Keravel S.à r.l, a company indirectly owned by CVC European Equity Fund V and CVC European Equity Tandem Fund, in the initial public offering of Ahlsell’s shares and listing on Nasdaq Stockholm (10/2016), as well as representing Keravel S.à r.l on its two post-IPO sell downs in Ahlsell;
  • Patricia Industries, a part of Investor AB, in its acquisition of LABORIE.
Career

Roschier, Partner (2011-)
Advokatfirman Vinge, Partner (2007-2011)
Advokatfirman Vinge, Associate (1998-2007)

Memberships

Member of the Swedish Bar Association

Education

Lund University, LL.M. (1998)
Stockholm School of Economics, M.Sc. (1995)

Languages

English, Swedish

Extremely friendly and knowledgeable about corporate laws in Sweden, very experienced in public M&A, with superior ability to crystalise complex legal analysis in plain English.

The Legal 500